O
Oliver Lenz
Researcher at Tibotec
Publications - 37
Citations - 1765
Oliver Lenz is an academic researcher from Tibotec. The author has contributed to research in topics: Hepatitis C virus & Protease. The author has an hindex of 19, co-authored 37 publications receiving 1725 citations. Previous affiliations of Oliver Lenz include Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz,Thierry Verbinnen,Tse-I Lin,Leen Vijgen,Maxwell D. Cummings,Jimmy Lindberg,Jan Martin Berke,Pascale Dehertogh,Els Fransen,Annick Scholliers,Katrien Vermeiren,Tania Ivens,Pierre Raboisson,Michael Edlund,Susan Storm,Lotta Vrang,Herman de Kock,Gregory Fanning,Kenneth Simmen +18 more
TL;DR: TMC435 remained active against replicons with the specific mutations observed after in vitro or in vivo exposure to telaprevir or boceprevir, and combinations of TMC435 with alpha interferon and NS5B polymerase inhibitors prevented the formation of drug-resistant replicon colonies.
Journal ArticleDOI
In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
Tse-I Lin,Oliver Lenz,Gregory Fanning,Thierry Verbinnen,Frederic Delouvroy,Annick Scholliers,Katrien Vermeiren,Åsa Rosenquist,Michael Edlund,Bertil Samuelsson,Lotta Vrang,Herman de Kock,Piet Wigerinck,Pierre Raboisson,Kenneth Simmen +14 more
TL;DR: TMC435350 is a highly specific and potent inhibitor of NS3/4A protease selected from a series of novel macrocyclic inhibitors that has the potential for combination with other anti-HCV agents and the favorable pharmacokinetic profile.
Journal ArticleDOI
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Paul Y. Kwo,Norman Gitlin,Ronald Nahass,David E. Bernstein,K.P. Etzkorn,Sergio Rojter,Eugene R. Schiff,M. Davis,Peter Ruane,Ziad Younes,R. Kalmeijer,Rekha Sinha,Monika Peeters,Oliver Lenz,Bart Fevery,Guy De La Rosa,Jane Scott,James Witek +17 more
TL;DR: Simeprevir+sofosbuvir for 12 weeks is highly effective in the treatment of HCV GT1‐infected patients without cirrhosis, including those with Q80K.
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Paul Y. Kwo,Norman Gitlin,Ronald Nahass,David E. Bernstein,K.P. Etzkorn,Sergio Rojter,Eugene R. Schiff,M. Davis,Peter Ruane,Ziad Younes,R. Kalmeijer,Rekha Sinha,Monika Peeters,Oliver Lenz,Bart Fevery,Guy De La Rosa,Jane Scott,James Witek +17 more
TL;DR: The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder HCV genotype (GT) 1-infected patients receiving simeprevir+sofosbuvir±ribavirin for 12 or 24 weeks.
Journal ArticleDOI
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Henk W. Reesink,Gregory Fanning,Khalid Abou Farha,Christine J. Weegink,Andre van Vliet,Gerben Albert Eleutherius Van 'T Klooster,Oliver Lenz,Fatima Aharchi,K. Marien,Pieter Van Remoortere,Herman de Kock,Fabrice Broeckaert,Paul Meyvisch,Els Van Beirendonck,Kenneth Simmen,R. Verloes +15 more
TL;DR: Once daily TMC435 given orally was generally safe and well tolerated and demonstrated potent antiviral activity, in a first-in-human trial.